Skip to main content
. Author manuscript; available in PMC: 2013 Sep 9.
Published in final edited form as: J Am Board Fam Med. 2009 Mar-Apr;22(2):187–195. doi: 10.3122/jabfm.2009.02.080059

Appendix Table 4.

Sensitivity Analysis Excluding All Persons Enrolled in Medicare Part D and With a Medicare Physician Office Visit From the VA Cohort*

Patients Using Brand-Name Drug Oral Hypoglycemics, % Insulin Analogues, % Statins, % ACE Inhibitors/ARBs, %
Patients excluded 10.8 11.0 10.5 10.2
VA original cohort 12.7 27.0 18.2 20.8
VA nondual user (sensitivity population) 12.8 26.3 18.3 20.6
VA dual users (excluded population) 11.8 33.0 17.8 22.1
Medicare cohort 35.3 75.1 50.7 42.5

ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; VA = Veterans Affairs.

*

“Medicare” refers to patients enrolled in fee-for-service Parts A and B and stand-alone Part D. “Statins” denotes 3-hydroxy-3-methyl coenzyme A reductase inhibitors. A total of 57 314 veterans (11% of the original VA cohort) were excluded.